ARTICLE | Product Development
March 4 Quick Takes: Arcturus-Duke-NUS collaborate on COVID-19 vaccine; plus Gilead, Roche, Editas-Allergan, Alnylam, FDA
March 5, 2020 1:50 AM UTC
Updated on Mar 5, 2020 at 1:55 AM UTC
Arcturus, Duke-NUS partner on COVID-19 vaccine
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) and Duke-NUS Medical School are collaborating to use the company’s STARR technology and the university’s rapid vaccine screening platform to develop a vaccine against SARS-CoV-2 for Singapore. Arcturus’ STARR platform combines self-replicating RNA with the company’s nanoparticle delivery system...